Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) EBIT Margin (2020 - 2025)

Ovid Therapeutics' EBIT Margin history spans 6 years, with the latest figure at 1712.12% for Q4 2025.

  • For Q4 2025, EBIT Margin changed N/A year-over-year to 1712.12%; the TTM value through Dec 2025 reached 585.2%, up 1204378.0%, while the annual FY2025 figure was 585.2%, 1034854.0% up from the prior year.
  • EBIT Margin reached 1712.12% in Q4 2025 per OVID's latest filing, up from 9487.12% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 84.73% in Q1 2021 to a low of 115329.27% in Q3 2022.
  • Average EBIT Margin over 5 years is 13878.78%, with a median of 8566.1% recorded in 2025.
  • The largest YoY upside for EBIT Margin was 10429349bps in 2023 against a maximum downside of -2075618bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 11.92% in 2021, then skyrocketed by 54bps to 5.47% in 2022, then crashed by -49bps to 8.16% in 2023, then plummeted by -93551bps to 7645.09% in 2024, then soared by 78bps to 1712.12% in 2025.
  • Per Business Quant, the three most recent readings for OVID's EBIT Margin are 1712.12% (Q4 2025), 9487.12% (Q3 2025), and 80.88% (Q2 2025).